AVITA Medical Inc. (NASDAQ: RCEL) announced interim results from its Cohealyx-I study showing reduced time to skin grafting for patients with full-thickness wounds. The study of 40 patients demonstrated a mean time to grafting of 13.6 days compared to a 33.2-day benchmark derived from published data on dermal matrices representing approximately 900 patients.

The results showed statistical superiority with a p-value of less than 0.001 versus the literature-derived benchmark. The median time to grafting was 11 days, with some patients receiving grafts as early as 5 days. Twenty-five percent of patients were grafted within 7 days, and 72% within 14 days.

Investigators reported 90% satisfaction at the time of grafting. The benchmark was derived from a meta-analysis of published data on leading dermal matrices.

"These interim results show that Cohealyx supports vascularization and enables earlier grafting, which is central to improving patient outcomes," said Derek Bell, Professor of Plastic Surgery and Kessler Burn Director at University of Rochester Medical Center.

Cohealyx is a collagen-based dermal matrix designed for use in staged surgical procedures for acute full-thickness wounds. The Cohealyx-I study is a prospective, single-arm, post-market, multi-center study evaluating safety and performance in patients with full-thickness wounds following surgical excision.

The study remains ongoing with full dataset expected in 2026. Patients are followed for approximately six months post-grafting to assess durability of outcomes and monitor adverse events. AVITA Medical will host a webinar on April 16 during the American Burn Association Annual Meeting to discuss the findings.